NCT06843681View on ClinicalTrials.gov

Trastuzumab Plus Taxane Neoadjuvant Therapy for HER2-Positive Breast Carcinoma: A Phase II Study

PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

January 1, 2027

Study Completion Date

January 1, 2030

Conditions
Breast Carcinoma in Situ
Interventions
DRUG

Trastuzumab combined with taxane neoadjuvant therapy

Trastuzumab combined with taxane neoadjuvant therapy

Trial Locations (1)

Unknown

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou

All Listed Sponsors
collaborator

Peking University Shenzhen Hospital

OTHER

lead

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER